There has also been one case report of fatal HHV-6 myelitis following CD19-targeted CAR T-cell therapy in a patient who developed CRS and ICANS that initially responded to corticosteroids with subsequent development of ascending flaccid paralysis (73). The gene discussed is CD19; the disease is congenital rubella syndrome.